All insights
Consultant prepRegulated Commercial ReadinessSource review as of 2026-06-06

When Three Regulatory Consultants Give You Three Different Answers

Picture the moment after the third consultant call. Three Regulatory Affairs / Quality Assurance (RA/QA) consultants all sounded credible, but each one seemed to be solving a different version of your product.

This is not only an advice problem. It is an assumptions problem. Before choosing who should build the plan, make the product facts, public sources, internal knowledge, open claims, and consultant assumptions visible on one page.

For medical-device Chief Executive Officers (CEOs), co-founders, and founder teams preparing for United States market-entry conversations.

Founder reviews three different regulatory-consultant notes before comparing assumptions for a medical-device market-entry decision.

The scene

Your notebook is open. One consultant talked about product category. One focused on intended use. One kept asking about evidence, performance data, comparator logic, and labeling language.

All three may be serious people. But if the assumptions behind the advice are hidden, the founder team ends up comparing confidence instead of comparing reasoning.

The wrong frame

The tempting question is, 'Which consultant do we like best?' The better question is, 'Which consultant is reasoning from the product we actually have, the customer we actually need to serve, and the evidence questions we actually need to resolve?'

The cost of getting this wrong is not only the consulting fee. It is months of regulatory planning, customer explanation, investor story, website language, and sales material built on assumptions nobody wrote down.

Build one comparison page before the next call

The founder does not need to become a regulatory expert overnight. The founder needs to make hidden assumptions visible before the company commits time, budget, and public language.

RowQuestion to answer
Product factWhat does the device do, for whom, and in what setting?
Current alternativeWhat would the customer use or do today?
Public vs. internal knowledgeWhat is source-supported in public records, and what only your team knows?
Open claimsWhat claims still need review before they appear in customer, investor, website, or sales material?
Consultant assumptionWhat route, category, comparator, evidence, or claim boundary is this advice assuming?
Question to ask againWhat fact would change this recommendation?

The founder-level move

After that page exists, you are no longer just buying confidence. You are comparing reasoning.

A strong consultant will welcome a sharper starting point. A weak fit will hide behind confidence.

TrueMedDevice can help organize public evidence, internal fact prompts, open claims, and review questions. The founder team, qualified RA/QA reviewer, consultant, legal advisor, or regulator still makes the professional judgment.

Source ledger

FDA, How to Study and Market Your Device

What it can tell you

The Food and Drug Administration (FDA) describes broad United States device market-entry steps, including classification, premarket submission selection, and registration / listing concepts.

What it cannot decide

A specific product's classification, submission route, consultant choice, commercial readiness, clearance, approval, safety, or effectiveness.

FDA, Premarket Notification 510(k)

What it can tell you

FDA describes the 510(k) substantial-equivalence concept and comparison to legally marketed devices where the 510(k) pathway applies.

What it cannot decide

Whether a specific product needs a 510(k), which predicate is suitable, or whether the product is substantially equivalent.

FDA, Content of a 510(k)

What it can tell you

FDA identifies content concepts such as indications for use, proposed labeling, device specifications, substantial-equivalence comparison, and performance information.

What it cannot decide

A company-specific submission plan, evidence sufficiency, or whether one consultant's advice is correct.

FDA, Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program

What it can tell you

FDA describes mechanisms for submitters to request FDA interactions related to medical-device submissions.

What it cannot decide

What questions a specific company should ask, how FDA will respond, or which consultant should be hired.

Frequently asked questions

Does this tell me which regulatory consultant to hire?

No. It gives the founder team a cleaner way to compare the assumptions behind consultant advice. It does not decide consultant suitability, regulatory pathway, classification, clearance, approval, safety, effectiveness, or legal obligations.

Why include FDA references if this is a founder communication article?

FDA sources are used as boundary references. They support the idea that intended use, labeling, comparator logic, and submission content can matter, but they do not decide any specific company's route or wording.

What should I do before the next consultant call?

Prepare one assumption map: product fact, current alternative, public versus internal knowledge, open claims, consultant assumption, and the question that should be asked again.

Need a one-page comparison before the next consultant call?

Request the Market-Ready Sales & Support Pack overview to see how one product, one buyer scene, and one consultant question become a review-ready comparison page.